Showing 1 – 1 of 1
Relevance | Newest | Oldest |
  • JAMA Original Investigation
    April 6, 2024

    Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial

    Richard M.听Martin,听BM, BS, PhD; Emma L.听Turner,听PhD; Grace J.听Young,听MSc; Chris听Metcalfe,听PhD; Eleanor I.听Walsh,听MSc; J. Athene听Lane,听PhD; Jonathan A. C.听Sterne,听PhD; Sian听Noble,听PhD; Peter听Holding,听MSc; Yoav听Ben-Shlomo,听MBBS, PhD; Naomi J.听Williams,听PhD; Nora听Pashayan,听MD, PhD; Mai Ngoc听Bui,听PhD; Peter C.听Albertsen,听MD; Tyler M.听Seibert,听MD, PhD; Anthony L.听Zietman,听MD; Jon听Oxley,听MD; Jan听Adolfsson,听MD; Malcolm D.听Mason,听MD; George听Davey Smith,听DSc; David E.听Neal,听MD; Freddie C.听Hamdy,听MD; Jenny L.听Donovan,听PhD; CAP Trial Group
    Abstract Full Text
    is active quiz has multimedia
    JAMA. 2024; 331(17):1460-1470. 10.1001/jama.2024.4011

    This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up.